Abstract
Aim:
The aim of the present study was to further elucidate the mechanism of the protective role of fluvastatin on diabetic nephropathy.
Methods:
Streptozotocin-induced diabetic rats were treated daily with fluvastatin (4 mg/kg body weight) by gavage. The animals were killed 4 weeks later and urine and blood samples were collected. The kidney tissues were removed and subjected to the following experiments. Rat glomerular mesangial cells (GMC) were cultured under normal glucose (5.5 mmol/L), high glucose (HG, 30 mmol/L), HG+AG490 (10 μmol/L), or HG with fluvastatin (1 μmol/L). Glomeruli or the GMC lysate was immunoprecipitated and/or immunoblotted with antibodies against Janus kinase 2 (JAK2), SH2-domain containing tyrosine phosphatase-1 (SHP-1), phosphospecific SHP-2, and signal transducer and activators of transcription (STAT), respectively. Transforming growth factor-β (TGF-β1) mRNA was measured by RT-PCR. The protein synthesis of TGF-β1 and fibronectin in the culture medium of GMC was detected by ELISA.
Results:
The phosphorylation levels of JAK2, STAT1, STAT3, and SHP-2 increased significantly, and SHP-1 phosphorylation was reduced in glomeruli of diabetic rats. Treatment with fluvastatin reduced phosphorylation levels of JAK2, STAT1, STAT3, and SHP-2 in glomeruli of diabetic rats, but it had no effect on the dephosphorylation of SHP-1. The exposure of GMC to 30 mmol/L glucose caused the activation of JAK2, STAT1, STAT3, and SHP-2. It upregulated TGF-β1 expression and increased protein synthesis of fibronectin. These high glucose-induced changes were suppressed by fluvastatin, as well as AG490, a JAK2 inhibitor.
Conclusion:
The regulation of the phosphorylation of JAK/STAT by fluvastatin may be responsible for its renal protective effects on diabetic nephropathy.
Similar content being viewed by others
Article PDF
References
Kim SI, Han DC, Lee HB . Lovastatin inhibits transforming growth factor-β1 expression in diabetic rat glomeruli and cultured rat mesangial cells. J Am Soc Nephrol 2000; 11: 80–7.
Oh JH, Ha H, Yu MR, Lee HB . Sequential effects of high glucose on mesangial cell transforming growth factor-β1 and fibronectin synthesis. Kidney Int 1998; 54: 1872–8.
Marrero MB, Banes AK, Stern DM, Eaton DC . Role of the JAK/ STAT signaling pathway in diabetic nephropathy. Am J Physiol Renal Physiol 2006; 290: F762–8.
Wang X, Shaw S, Amiri F, Eaton DC, Marrero MB . Inhibition of the Jak/STAT signaling pathway prevents the high glucose-induced increase in tgf-beta and fibronection synthesis in mesangial cells. Diabetes 2002; 51: 3505–9.
Aaronson DS, Horvath CM . A road map for those who don't know JAK-STAT. Science 2002; 296: 1653–5.
Darnell JE, Kerr IM, Stark GR . Jak-STAT pathways and transcriptional activation in response to INFs and other extracellular signaling proteins. Science 1994; 264: 1415–21.
Amiri F, Shaw S, Wang X, Tang J, Waller JL, Eaton DC, et al. Angiotensin II activation of the JAK/STAT pathway in mesangial cells is altered by high glucose. Kidney Int 2002; 61: 1605–16.
Amiri F, Venema VJ, Wang X, Ju H, Venema RC, Marrero MB . Hyperglycemia enhances angiotensin II-induced janus-activated kinase/STAT signaling in vascular smooth muscle cells. J Biol Chem 1999; 274: 32382–6.
Banes AK, Shaw S, Jenkins J, Redd H, Amiri F, Pollock DM, et al. Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli. Am J Physiol Renal Physiol 2004; 286: F653–9.
Oda H, Keane WF . Recent advances in statins and the kidney. Kidney Int Suppl 1999; 71: 2–5.
Kurusu A, Shou I, Nakamura S, Fukui M, Shirato I, Tomino Y . Effects of the new hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin on anti-oxidant enzyme activities and renal function in streptozotocin-induced diabetic rats. Clin Exp Pharmacol Physiol 2000; 27: 767–70.
Shibata S, Nagase M, Fujita T . Fluvastatin ameliorates podocyte injury in proteinuric rats via modulation of excessive Rho signaling. J Am Soc Nephrol 2006; 17: 754–64.
Horiuchi M, Cui T, Li Z, Li J, Nakagami H, Iwai M . Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, vasartan, on vascular neointimal formation. Circulation 2003; 107: 106–12.
Banes AK, Shaw S, Ma G, Brands M, Eaton DC, Stern DM, et al. Effect of simvastatin on high glucose- and angiotensin II-induced activation of the JAK/STAT pathway in mesangial cells. Am J Physiol Renal Physiol 2006; 291: F116–21.
Amiri F, Garcia R . Renal angiotensin II receptors and protein kinase C in diabetic rats: effects of insulin and ACE inhibition. Am J Physiol Renal Physiol 2000; 278: F603–12.
Amiri F, Garcia R . Regulation of angiotensin II receptors and PKC isoforms by glucose in rat mesangial cells. Am J Physiol 1999; 276: F691–9.
Shah S, Paparello J, Danesh FR . Effects of statin therapy on the progression of chronic kidney disease. Adv Chronic Kidney Dis 2005; 12: 187–95.
Ota T, Takamura T, Ando H, Nohara E, Yamashita H, Kobayashi K . Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. Diabetologia 2003; 46: 843–51.
Wolf G . Vasoactive factors and tubulointerstitial injury. Kidney Blood Press Res 1999; 22: 62–70.
Hannken T, Schroeder R, Stahl RAK, Wolf G . Atrial natriuretic peptide attenuates Ang II induced hypertrophy of renal tubular cells. Am J Physiol 2001; 281: F81–90.
Ling H, Vamvakas S, Schaefer L, Schnittler HJ, Schaefer RM, Heidland A . Angiotensin II induced cell hypertrophy: potential role of impaired proteolytic activity in cultured LLcpk1 cells. Nephrol Dialysis Transplant 1995; 10: 1305–12.
Guo XH, Liu ZH, Dai CS, Li H, Liu D, Li LS . Rhein inhibits renal tubular epithelial cell hypertrophy and extracellular matrix accumulation induced by transforming growth factor β. Acta Pharmacol Sin 2001; 22: 934–8.
Park IS, Kiyomoto H, Abboud SL, Abboud HE . Expression of transforming growth factor β and type IV collagen in early streptozotocin-induced diabetes. Diabetes 1997; 46: 473–80.
Ziyadeh FN . Mediators of diabetic renal disease: the case for TGF-β as the major mediator. J Am Soc Nephrol 2004; 15: S55–7.
Marrero MB, Venema VJ, Ju H, Eaton DC, Venema RC . Regulation of angiotensin II-induced JAK2 tyrosine phosphorylation: roles of SHP-1 and SHP-2. Am J Physiol Cell Physiol 1998; 275: C1216–23.
Meng TC, Fukada T, Tonks NK . Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol Cell 2002; 9: 387–99.
Denu JM, Tanner KG . Specific and reversible inactivation of protein tyrosine phosphatases by hydrogen peroxide: evidence for a sulfenic acid intermediate and implications for redox regulation. Biochemistry 1998; 37: 5633–42.
Ha H, Lee HB . Reactive oxygen species and matrix remodeling in diabetic kidney. J Am Soc Nephrol 2003; 14: S246–S249.
Schaefer CA, Kuhlmann CR, Weiterer S, Fehsecke A, Abdallah Y, Schaefer C, et al. Statins inhibit hypoxia-induced endothelial proliferation by preventing calcium-induced ROS formation. Atherosclerosis 2006; 185: 290–6.
Wassmann S, Laufs U, Baumer AT, Muller K, Konkol C, Sauer H, et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol 2001; 59: 646–54.
Ali MS, Schieffer B, Delafontaine P, Bernstein KE, Ling BN, Marrero MB . Angiotensin II stimulates tyrosine phosphorylation and activation of insulin receptor substrate 1 and protein-tyrosine phosphatase 1D in vascular smooth muscle cells. J Biol Chem 1997; 272: 12373–9.
Ichiki T, Takeda K, Tokunou T, Iino N, Egashira K, Shimokawa H, et al. Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2001; 21: 1896–901.
Author information
Authors and Affiliations
Corresponding author
Additional information
Project supported by the Hebei Provincial Natural Science Fund (C2004000536).
Rights and permissions
About this article
Cite this article
Shi, Yh., Zhao, S., Wang, C. et al. Fluvastatin inhibits activation of JAK and STAT proteins in diabetic rat glomeruli and mesangial cells under high glucose conditions. Acta Pharmacol Sin 28, 1938–1946 (2007). https://doi.org/10.1111/j.1745-7254.2007.00653.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2007.00653.x